Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

Journal of Medicinal Chemistry

Volumn 43, Issue 9, 2000, Pages 1664-1669

  Knudsen, Lotte B ^a   Nielsen, Per F ^a   Huusfeldt, Per O ^a   Johansen, Nils L ^a   Madsen, Kjeld ^a   Pedersen, Freddy Z ^a   Thøgersen, Henning ^a   Wilken, Michael ^a   Agersø, Henrik ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HORMONE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ACYLATION; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; KIDNEY; LYSINE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN PRECURSORS; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

EID: 0034108646     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9909645     Document Type: Article

References (33)

1. Nauck, M. A.; Heimesaat, M. M.; Ørskov, C.; Holst, J. J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of GLP-1(7-36amide) but not of synthetic human GIP in patients with type 2-diabetes mellitus. J. Clin. Invest. 1993, 91, 301-307.
2. Nathan, D. M.; Schreiber, E.; Fogel, H.; Mojsov, S.; Habener, J. F. Insulinotropic action of GLP-1-(7-37) in diabetic and non-diabetic subjects. Diabetes Care 1992, 15, 270-276.
3. Gutniak, M. K.; Linde, B.; Holst, J. J.; Efendic, S. Subcutaneous injection of the incretin hormone GLP-1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994, 17, 1039-1044.
4. Nauck, M. A.; Kleine, N.; Ørskov, C.; Holst, J. J.; Willms, B.; Creutzfeldt, W. Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36) amide in type 2-diabetic patients. Diabetologia 1993, 36, 741-744.
5. Kreymann, B.; Ghatai, M. A.; Williams, G.; Bloom, S. R. GLP-1 7-36: a physiological incretin in man. Lancet 1987, II, 1300-1304.
6. Rachman, J.; Barrow, B. A.; Levy, J. C.; Turner, R. C. Near-normalization of diurnal glucose concentrations by continuous administration of GLP-1 in subjects with NIDDM. Diabetologia 1997, 40, 205-211.
7. Larsen, J.; Jallad, N.; Damsbo, P. One-week infusion of GLP-1 improves the glycemic control in NIDDM. Diabetes 1996, 45, 860.
8. Qualmann, C.; Nauck, M.; Holst, J. J.; Ørskov, C.; Creutzfeldt, W. Insulinotropic actions of intravenous glucagon-like peptide-1 (7-36) amide in the fasting state in healthy subjects. Acta Diabetol. 1995, 32, 13-16.
9. Toft-Nielsen, M.; Madsberg, S.; Holst, J. J. Exaggerated secretion of GLP-1 could cause reactive hypoglycaemia. Diabetologia 1998, 41, 1180-1186.
10. Wettergren, A.; Schjoldager, B.; Mortensen, P. E.; Myhre, J.; Christiansen, J.; Holst, J. J. Truncated GLP-1 (proglucagon 72-107amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 1993, 38, 665-673.
11. Nauck, M. A.; Niederereichholz, U.; Ettler, R.; Holst, J. J.; Ørskov, C.; Ritzel, R.; Schmigel, W. H. Glucagon-like peptide-1 inhibition of gastric-emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol 1997, 273, E981-E988.
12. Nauck, M. A. Is GLP-1 an incretin hormone?. Diabetologia 1999, 42, 373-379.
13. Flint, A.; Raben, A.; Astrup, A.; Holst, J. J. GLP-1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 1998, 101, 515-520.
14. Näslund, E.; Gutniak, M. K; Skogar, S.; Rössner, S.; Hellström, P. M. GLP-1 increases the period of postprandial satiety and slows gastric emptying in obese humans. Am. J. Clin. Nutr. 1998, 68, 525-530.
15. Gutzwiller, J. P.; Göke, B.; Drewe, J.; Hildebrand, P.; Ketterer, S.; Handscin, D.; Winterhalder, R.; Conen, D.; Beglinger, C. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 44, 81-86.
16. Edvell, A.; Lindström, P. Initiation of increased pancreatic islet growth in young normoglycaemic mice (Umeå +/?). Endocrinology 1999, 140, 778-783.
17. Clodfelter, D. K.; Pekar, A. H.; Rebhun, D. M.; Destrampe, K. A.; Havel, H. A.; Myers, S. R.; Brader, M. L. Effects of noncovalent self-association on the subcutaneous absorption of a therapeutic peptide. Pharm. Res. 1998, 15, 254-262.
18. Deacon, C. F.; Johnsen, A. H.; Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80, 952-957.
19. Kieffer, T. J.; McIntosh, C. H. S.; Pederson, R. A. Degradation of GIP and truncated GLP-1 in vitro and in vivo by Dipeptidyl Peptidase IV. Endocrinology 1995, 736, 585-3596.
20. Knudsen, L. B.; Pridal, L. GLP-1(9-36)amide is major metabolite of GLP-1(7-36)amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmaml. 1996, 318, 429-435.
21. Deacon, C. F.; Knudsen, L. B.; Madsen, K.; Wiberg, F. C.; Jacobsen, O.; Holst, J. J. Dipeptidyl peptidase IV resistant analogues of GLP-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998, 41, 271-278.
22. Kurtzhals, P.; Havelund, S.; Jonassen, I.; Kiehr, B.; Larsen, U. D.; Ribel, U.; Markussen, J. Albumin-binding of insulins acylated with fatty-acids - characterization of the ligand protein-interaction and correlation between binding-affinity and timing of the insulin effect in-vivo. Biochem. J. 1995, 312, 725-731.
23. Markussen, J.; Havelund, S.; Kurtzhals, P.; Andersen, A. S.; Halstøm, J.; Hasselager, E.; Larsen, U. D.; Ribel, U.; Schaffer, L.; Vad, K.; Jonassen, I. Soluble, fatty-acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996, 39, 281-288.
24. Kurtzhals, P.; Havelund, S.; Jonassen, I.; Kiehr, B.; Ribel, U.; Markussen, J. Albumin-binding and time action of acylated insulins in various species. J. Pharm. Sci. 1996, 85, 304-308.
25. Myers, S. R.; Yakubumadus, F. E.; Johnson, W. T.; Baker, J. E.; Cusick, T. S.; Williams, V. K.; Tinsly, F. C.; Kriauciunas, A.; Manetta, J.; Chen, V. J. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 1997, 46, 637-642.
26. Kenyon, M. A.; Hamilton, J. A. 13C NMR studies of the binding of medium-chain fatty acids to human serum albumin. J. Lipid Res. 1994, 35, 458-467.
27. Adelhorst, K.; Heedegaard, B. B.; Knudsen, L. B.; Kirk, O. Structure activity studies of GLP-1. J. Biol. Chem. 1994, 269, 6275-6278.
28. Buckley, D. I.; Habener, J. F.; Mallory, J. B.; Mojsov, S. GLP-1 analogues useful for diabetes treatment. U.S. Patent 5,545,618.
29. Chen, V. J.; DiMarchi, R. D.; Smiley, D. L.; Stucky, R. D.; Kriauciunas, A. V. Glucagon-Like insulinotropic peptide analogues, compositions, and methods of use. U.S. Patent 5,512,-549.
30. Ebashi, I.; Takigawa, T.; Inoue, M. Long chain carboxylic acid imide ester. EP511600.
31. Knudsen, L. B.; Nielsen, P. F.; Sørensen, P. O. GLP-1 derivatives which have lipophilic substituent - exhibit protracted profiles of action relative to known GLP-1 compounds and are useful in treatment of diabetes. WO9808871.
32. Paquet, A. Succinimidyl esters of fatty-acids for amino acid acylations. Can. J. Chem. 1976, 54, 733-737.
33. Suskovic, B.; Vajtner, Z.; Naumski, R. Synthesis and biological activities of some peptidoglycan monomer derivatives. Tetrahedron 1991, 47, 8407-8416.